| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Institute of Molecular Immunology, GSF National Research Center for the Environment and Health, Munich, Germany;
Institute of Clinical and Molecular Virology, Friedrich Alexander University of Erlangen-Nurnberg, Erlangen, Germany;
Institute of Anthropology and Human Genetics, Ludwig Maximilians University, Munich, Germany;
Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic;
¶ Max von Pettenkofer Institute, Department of Virology, Ludwig Maximilians University, Munich, Germany
A highly attractive approach to investigate the influence and hierarchical organization of viral proteins on cellular immune responses is to employ mutant viruses carrying deletions of various virus-encoded, immune-modulating genes. Here, we introduce a novel set of deletion mutants of the human CMV (HCMV) lacking the UL40 region either alone or on the background of a deletion mutant devoid of the entire US2–11 region. Deletion of UL40 had no significant effect on lysis of infected cells by NK cells, indicating that the expected enhancement of HLA-E expression by specific peptides derived from HCMV-encoded gpUL40 leader sequences was insufficient to confer target cell protection. Moreover, the kinetics of MHC class I down-regulation by US2–11 genes observed at early and late phases postinfection with wild-type virus correlated with increased susceptibility to NK lysis. Thus, the influence of HCMV genes on NK reactivity follows a hierarchy dominated by the US2–11 region, which encodes all viral genes capable of down-modulating expression of classical and non-classical MHC class I molecules. The insights gained from studies of such virus mutants may impact on future therapeutic strategies and vaccine development and incorporate NK cells in the line of defense mechanisms against HCMV infection.
This article has been cited by other articles:
|
|
 |
|
  L. Mandic, M. S. Miller, C. Coulter, B. Munshaw, and L. Hertel Human cytomegalovirus US9 protein contains an N-terminal signal sequence and a C-terminal mitochondrial localization domain, and does not alter cellular sensitivity to apoptosis J. Gen. Virol., May 1, 2009; 90(5): 1172 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Mersseman, K. Besold, M. J. Reddehase, U. Wolfrum, D. Strand, B. Plachter, and S. Reyda Exogenous introduction of an immunodominant peptide from the non-structural IE1 protein of human cytomegalovirus into the MHC class I presentation pathway by recombinant dense bodies J. Gen. Virol., February 1, 2008; 89(2): 369 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Besold, N. Frankenberg, S. Pepperl-Klindworth, J. Kuball, M. Theobald, G. Hahn, and B. Plachter Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2-11-mediated immune evasion J. Gen. Virol., May 1, 2007; 88(5): 1429 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shin, B. Park, S. Lee, Y. Kim, B. J. Biegalke, S. Kang, and K. Ahn A Short Isoform of Human Cytomegalovirus US3 Functions as a Dominant Negative Inhibitor of the Full-Length Form. J. Virol., June 1, 2006; 80(11): 5397 - 5404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Guma, M. Budt, A. Saez, T. Brckalo, H. Hengel, A. Angulo, and M. Lopez-Botet Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts Blood, May 1, 2006; 107(9): 3624 - 3631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Barel, N. Pizzato, P. Le Bouteiller, E. J. H. J. Wiertz, and F. Lenfant Subtle sequence variation among MHC class I locus products greatly influences sensitivity to HCMV US2- and US11-mediated degradation Int. Immunol., January 1, 2006; 18(1): 173 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Wills, O. Ashiru, M. B. Reeves, G. Okecha, J. Trowsdale, P. Tomasec, G. W. G. Wilkinson, J. Sinclair, and J. G. P. Sissons Human Cytomegalovirus Encodes an MHC Class I-Like Molecule (UL142) That Functions to Inhibit NK Cell Lysis J. Immunol., December 1, 2005; 175(11): 7457 - 7465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Loveland, C.-K. Chan, E. J. Brignole, and W. Gibson Cleavage of Human Cytomegalovirus Protease pUL80a at Internal and Cryptic Sites Is Not Essential but Enhances Infectivity J. Virol., October 15, 2005; 79(20): 12961 - 12968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nattermann, H. D. Nischalke, V. Hofmeister, G. Ahlenstiel, H. Zimmermann, L. Leifeld, E. H. Weiss, T. Sauerbruch, and U. Spengler The HLA-A2 Restricted T Cell Epitope HCV Core35-44 Stabilizes HLA-E Expression and Inhibits Cytolysis Mediated by Natural Killer Cells Am. J. Pathol., February 1, 2005; 166(2): 443 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Barel, M. Ressing, N. Pizzato, D. van Leeuwen, P. Le Bouteiller, F. Lenfant, and E. J. H. J. Wiertz Human Cytomegalovirus-Encoded US2 Differentially Affects Surface Expression of MHC Class I Locus Products and Targets Membrane-Bound, but Not Soluble HLA-G1 for Degradation J. Immunol., December 15, 2003; 171(12): 6757 - 6765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Herzer, C. S. Falk, J. Encke, S. T. Eichhorst, A. Ulsenheimer, B. Seliger, and P. H. Krammer Upregulation of Major Histocompatibility Complex Class I on Liver Cells by Hepatitis C Virus Core Protein via p53 and TAP1 Impairs Natural Killer Cell Cytotoxicity J. Virol., August 1, 2003; 77(15): 8299 - 8309. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
